Ipodate

Summary

Ipodate (CHEMBL1201243) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 597.96 Da · C12H13I3N2O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201243
Name	Ipodate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5241
Molecular formula	C12H13I3N2O2
Molecular weight	597.96
InChIKey	YQNFBOJPTAXAKV-UHFFFAOYSA-N

SMILES: CN(C)C=NC1=C(C=C(C(=C1I)CCC(=O)O)I)I

IUPAC name: 3-[3-(dimethylaminomethylideneamino)-2,4,6-triiodophenyl]propanoic acid

Also known as: Iopodic acid, Ipodic acid, SID50125802, iopodic-acid

Parent form; salt/anhydrous children: CHEMBL1201033, CHEMBL2068725

Patent coverage: 347 distinct patent families (1,430 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 1,423 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).